Moderna, Inc. (MRNA)
Biological Products, (No Diagnostic Substances) · Biological Products, (No Diagnostic Substances) · NASDAQ
$174.38
+176.97%
Investingg Score
39.8 / 100
Sell
Business overview
- Gross margin stands at 55.3 percent.
- Operating margin is negative at 158.1 percent.
- FCF margin is negative at 106.2 percent.
These margins reflect a business that retains decent gross profitability on products, but currently incurs heavy operating and free cash flow losses relative to its revenue.
Financial health
- Balance sheet pillar score is 88.
- Financial quality pillar score is 8.
- Risk pillar score is 50.
While the strong balance sheet score highlights underlying asset stability, the low financial quality score points to fundamental profitability strains.
- Gross Margin
- 55.3%
- Operating Margin
- -158.1%
- Current Ratio
- 3.3x
- Debt / Equity
- 0.07
- Free Cash Flow (TTM)
- $-2.1B
- Interest Coverage
- Data unavailable
Valuation
- Price-to-sales ratio is 40.61.
- Free cash flow yield is negative 3 percent.
- Valuation pillar score is 23.
These metrics indicate an expensive sales multiple combined with negative cash flow generation, presenting valuation headwinds.
- P/E (TTM)
- Data unavailable
- Forward P/E
- Data unavailable
- Price / Sales
- 40.6x
- EV / EBITDA
- Data unavailable
- FCF Yield
- -3.0%
Key risks
- Data unavailable for specific forward-looking operational risk factors outside of the provided dataset.
- Negative operating and free cash flow margins create ongoing financial uncertainty.
- Revenue contraction year-over-year poses fundamental business sustainability questions.
Market cap $68.7B · data as of 2026-08-19
Related stocks
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze MRNA with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.